WA
TNGX icon

WPG Advisers’s Tango Therapeutics TNGX Stock Holding History

WPG Advisers’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63K Sell
78
-81
-51% -$1.13K ﹤0.01% 1146
2025
Q4 		$1.41K Buy
+159
New +$1.37K ﹤0.01% 1221

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

WPG Advisers's TNGX Position: Q1 2026 in Review

WPG Advisers reduced its Tango Therapeutics (TNGX) stake by 51% in Q1 2026, selling an estimated $1.13K and leaving 78 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

WPG Advisers first reported a position in TNGX in Q4 2025 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • WPG Advisers held 78 shares of Tango Therapeutics worth $1.63K as of Q1 2026.
  • WPG Advisers sold 81 Tango Therapeutics shares in Q1 2026, an estimated $1.13K.
  • Tango Therapeutics made up ﹤0.01% of WPG Advisers's portfolio in Q1 2026, its #1146 holding.
  • WPG Advisers first reported a position in Tango Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on WPG Advisers's 13F filing for Q1 2026, filed 30 Apr 2026.